Literature DB >> 26041615

Eye-tracking controlled cognitive function tests in patients with amyotrophic lateral sclerosis: a controlled proof-of-principle study.

Jürgen Keller1, Martin Gorges, Hannah T Horn, Helena E A Aho-Özhan, Elmar H Pinkhardt, Ingo Uttner, Jan Kassubek, Albert C Ludolph, Dorothée Lulé.   

Abstract

Amyotrophic lateral sclerosis (ALS) primarily affects motor and speech abilities. In addition, cognitive functions are impaired in a subset of patients. There is a need to establish an eye movement-based method of neuropsychological assessment suitable for severely physically impaired patients with ALS. Forty-eight ALS patients and thirty-two healthy controls matched for age, sex and education performed a hand and speech motor-free version of the Raven's coloured progressive matrices (CPM) and the D2-test which had been especially adapted for eye-tracking control. Data were compared to a classical motor-dependent paper-pencil version. The association of parameters of the eye-tracking and the paper-pencil version of the tests and the differences between and within groups were studied. Subjects presented similar results in the eye-tracking and the corresponding paper-pencil versions of the CPM and D2-test: a correlation between performance accuracy for the CPM was observed for ALS patients (p < 0.001) and controls (p < 0.001) and in the D2-test for controls (p = 0.048), whereas this correlation did not reach statistical significance for ALS patients (p = 0.096). ALS patients performed worse in the CPM than controls in the eye-tracking (p = 0.053) and the paper-pencil version (p = 0.042). Most importantly, eye-tracking versions of the CPM (p < 0.001) and the D2-test (p = 0.024) reliably distinguished between more and less cognitively impaired patients. Eye-tracking-based neuropsychological testing is a promising approach for assessing cognitive deficits in patients who are unable to speak or write such as patients with severe ALS.

Entities:  

Mesh:

Year:  2015        PMID: 26041615     DOI: 10.1007/s00415-015-7795-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Cognitive function in patients with late stage amyotrophic lateral sclerosis.

Authors:  J Lakerveld; B Kotchoubey; A Kübler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-22       Impact factor: 10.154

3.  The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: a cross-sectional comparison of established screening tools in a German-Swiss population.

Authors:  Dorothée Lulé; Christian Burkhardt; Susanne Abdulla; Sarah Böhm; Katja Kollewe; Ingo Uttner; Sharon Abrahams; Thomas H Bak; Susanne Petri; Markus Weber; Albert C Ludolph
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-08       Impact factor: 4.092

4.  The association between alterations of eye movement control and cerebral intrinsic functional connectivity in Parkinson's disease.

Authors:  Martin Gorges; Hans-Peter Müller; Dorothée Lulé; Elmar H Pinkhardt; Albert C Ludolph; Jan Kassubek
Journal:  Brain Imaging Behav       Date:  2016-03       Impact factor: 3.978

5.  Neurobehavioral symptoms in ALS are negatively related to caregivers' burden and quality of life.

Authors:  A Chiò; A Vignola; E Mastro; A Dei Giudici; B Iazzolino; A Calvo; C Moglia; A Montuschi
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

6.  EyeSeeCam: an eye movement-driven head camera for the examination of natural visual exploration.

Authors:  Erich Schneider; Thomas Villgrattner; Johannes Vockeroth; Klaus Bartl; Stefan Kohlbecher; Stanislavs Bardins; Heinz Ulbrich; Thomas Brandt
Journal:  Ann N Y Acad Sci       Date:  2009-05       Impact factor: 5.691

7.  Cognitive changes predict functional decline in ALS: a population-based longitudinal study.

Authors:  Marwa Elamin; Peter Bede; Susan Byrne; Norah Jordan; Laura Gallagher; Brona Wynne; Caoimhe O'Brien; Julie Phukan; Catherine Lynch; Niall Pender; Orla Hardiman
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910

8.  Brain communication in a completely locked-in patient using bedside near-infrared spectroscopy.

Authors:  Guillermo Gallegos-Ayala; Adrian Furdea; Kouji Takano; Carolin A Ruf; Herta Flor; Niels Birbaumer
Journal:  Neurology       Date:  2014-04-30       Impact factor: 9.910

9.  Screening for cognition and behaviour changes in ALS.

Authors:  Sharon Abrahams; Judith Newton; Elaine Niven; Jennifer Foley; Thomas H Bak
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-06-19       Impact factor: 4.092

10.  Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients' behavioral changes than physical disability: a comparative study.

Authors:  Patricia Lillo; Eneida Mioshi; John R Hodges
Journal:  BMC Neurol       Date:  2012-12-07       Impact factor: 2.474

View more
  9 in total

1.  An eye-tracker controlled cognitive battery: overcoming verbal-motor limitations in ALS.

Authors:  Barbara Poletti; Laura Carelli; Federica Solca; Annalisa Lafronza; Elisa Pedroli; Andrea Faini; Nicola Ticozzi; Andrea Ciammola; Paolo Meriggi; Pietro Cipresso; Dorothée Lulé; Albert C Ludolph; Giuseppe Riva; Vincenzo Silani
Journal:  J Neurol       Date:  2017-05-13       Impact factor: 4.849

2.  An eye-tracking controlled neuropsychological battery for cognitive assessment in neurological diseases.

Authors:  Barbara Poletti; Laura Carelli; Federica Solca; Annalisa Lafronza; Elisa Pedroli; Andrea Faini; Stefano Zago; Nicola Ticozzi; Andrea Ciammola; Claudia Morelli; Paolo Meriggi; Pietro Cipresso; Dorothée Lulé; Albert C Ludolph; Giuseppe Riva; Vincenzo Silani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

3.  An ERP-based BCI with peripheral stimuli: validation with ALS patients.

Authors:  Yangyang Miao; Erwei Yin; Brendan Z Allison; Yu Zhang; Yan Chen; Yi Dong; Xingyu Wang; Dewen Hu; Andrzej Chchocki; Jing Jin
Journal:  Cogn Neurodyn       Date:  2019-06-11       Impact factor: 5.082

4.  Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Jürgen Keller; Martin Gorges; Helena E A Aho-Özhan; Ingo Uttner; Erich Schneider; Jan Kassubek; Elmar H Pinkhardt; Albert C Ludolph; Dorothée Lulé
Journal:  J Vis Exp       Date:  2016-10-13       Impact factor: 1.355

5.  The Arrows and Colors Cognitive Test (ACCT): A new verbal-motor free cognitive measure for executive functions in ALS.

Authors:  Barbara Poletti; Laura Carelli; Andrea Faini; Federica Solca; Paolo Meriggi; Annalisa Lafronza; Luciana Ciringione; Elisa Pedroli; Nicola Ticozzi; Andrea Ciammola; Pietro Cipresso; Giuseppe Riva; Vincenzo Silani
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

6.  Screening for Cognitive Function in Complete Immobility Using Brain-Machine Interfaces: A Proof of Principle Study.

Authors:  Dorothée Lulé; Katharina Hörner; Cynthia Vazquez; Helena Aho-Özhan; Jürgen Keller; Martin Gorges; Ingo Uttner; Albert C Ludolph
Journal:  Front Neurosci       Date:  2018-08-15       Impact factor: 4.677

Review 7.  New technologies and Amyotrophic Lateral Sclerosis - Which step forward rushed by the COVID-19 pandemic?

Authors:  Susana Pinto; Stefano Quintarelli; Vincenzo Silani
Journal:  J Neurol Sci       Date:  2020-08-05       Impact factor: 3.181

Review 8.  Recent advances in amyotrophic lateral sclerosis.

Authors:  Nilo Riva; Federica Agosta; Christian Lunetta; Massimo Filippi; Angelo Quattrini
Journal:  J Neurol       Date:  2016-03-30       Impact factor: 4.849

Review 9.  Communication Matters-Pitfalls and Promise of Hightech Communication Devices in Palliative Care of Severely Physically Disabled Patients With Amyotrophic Lateral Sclerosis.

Authors:  Katharina Linse; Elisa Aust; Markus Joos; Andreas Hermann
Journal:  Front Neurol       Date:  2018-07-27       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.